Pfizer, Inc. (PFE) Position Decreased by Hartford Investment Management Co.
Hartford Investment Management Co. lessened its holdings in Pfizer, Inc. (NYSE:PFE) by 15.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,373,279 shares of the biopharmaceutical company’s stock after selling 258,647 shares during the period. Pfizer comprises about 0.9% of Hartford Investment Management Co.’s portfolio, making the stock its 16th largest holding. Hartford Investment Management Co.’s holdings in Pfizer were worth $46,128,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Northstar Group Inc. grew its position in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares during the period. Stone House Investment Management LLC increased its stake in shares of Pfizer by 0.9% during the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares in the last quarter. Naples Global Advisors LLC increased its stake in shares of Pfizer by 0.3% during the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares in the last quarter. Alpha Windward LLC increased its stake in shares of Pfizer by 1.1% during the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 89 shares in the last quarter. Finally, Asset Planning Services Ltd. increased its stake in shares of Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. 69.00% of the stock is owned by institutional investors.
In other Pfizer news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now owns 124,774 shares of the company’s stock, valued at $4,242,316. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/03/pfizer-inc-pfe-position-decreased-by-hartford-investment-management-co.html.
Pfizer, Inc. (PFE) traded down 0.2889% during midday trading on Tuesday, reaching $35.9658. The company’s stock had a trading volume of 6,000,942 shares. The company has a 50 day moving average price of $34.40 and a 200 day moving average price of $33.63. The firm has a market cap of $213.90 billion, a price-to-earnings ratio of 26.3100 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.21. Pfizer also was the target of unusually large options trading on Monday. Stock traders bought 24,211 call options on the company. This represents an increase of 129% compared to the typical volume of 10,577 call options.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the company posted $0.64 EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.55%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
PFE has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Tuesday. Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Jefferies Group LLC set a $37.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday, September 18th. Finally, BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.25.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.